| P2093 | author name string | Edward P Acosta | |
| | Jennifer R King | |
| | Mary C Long | |
| P2860 | cites work | Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors | Q46968863 |
| | Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance | Q47776364 |
| | Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. | Q51740971 |
| | Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910874 |
| | Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910877 |
| | Optimal drug treatment regimens for HIV depend on adherence. | Q51921692 |
| | Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals | Q79390358 |
| | HIV entry inhibitors: mechanisms of action and resistance pathways | Q28296162 |
| | Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials | Q31108441 |
| | Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity | Q34123595 |
| | A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy | Q34184881 |
| | Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors | Q34458371 |
| | Novel HIV-1 reverse transcriptase inhibitors. | Q34756615 |
| | Protein binding in antiretroviral therapies | Q35571186 |
| | The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities | Q35676408 |
| | Pharmacokinetic enhancement of protease inhibitor therapy | Q35744425 |
| | Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors | Q35866777 |
| | New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections | Q35879802 |
| | The intracellular pharmacology of antiretroviral protease inhibitors | Q35945501 |
| | The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing | Q36180411 |
| | Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors | Q36498272 |
| | Antiretroviral pharmacokinetic profile: a review of sex differences | Q36914113 |
| | Tipranavir: a new option for the treatment of drug-resistant HIV infection | Q36916096 |
| | Clinical pharmacokinetics of darunavir | Q36916791 |
| | Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients | Q36949483 |
| | Darunavir: a nonpeptidic antiretroviral protease inhibitor | Q36962404 |
| | Maraviroc | Q36967178 |
| | CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1. | Q36969728 |
| | Antiretroviral therapy : optimal sequencing of therapy to avoid resistance | Q37032556 |
| | Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. | Q37093753 |
| | Adherence to protease inhibitor therapy and outcomes in patients with HIV infection | Q39605935 |
| | TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. | Q40425001 |
| | TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments | Q42033549 |
| | The binding of HIV-1 protease inhibitors to human serum proteins | Q44590334 |
| | An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance | Q44699308 |
| | Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme | Q45402590 |
| | Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial | Q45405108 |
| | Emergence of an NNRTI resistance mutation Y181C in an HIV-infected NNRTI-naive patient | Q46712730 |
| | Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase | Q46843159 |
| | Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers | Q46878762 |
| | Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. | Q46900196 |
| | Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products | Q46930423 |
| P433 | issue | 6 | |
| P921 | main subject | anti-retroviral agent | Q50430310 |
| P304 | page(s) | 522-529 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | Current infectious disease reports | Q26842136 |
| P1476 | title | Pharmacologic aspects of new antiretroviral drugs. | |
| P478 | volume | 10 | |